קטגוריה:Pharmacological subgroup

×¨×× ×©×××©××ª ×©× ×§×× ATC â ×ª×ª-×§×××¦× ×¤×¨××§××××××ª

×§××××¨×××ª ××©× ×

××£ ×§××××¨×× ×× ×××× ××ª 200 ×§××××¨×××ª ×××©× × ×××××ª, ××ª×× 270 ××§××××¨×× ××××.

(200 ××§×××××) (200 ×××××)

A

ACE inhibitors, combinations - C09Bâ (2 ×§×', 6 ××¤××)
ACE inhibitors, plain - C09Aâ (×§×' ×××ª, 37 ××¤××)
Adrenergics for systemic use - R03Câ (4 ×§×', 4 ××¤××)
Adrenergics, inhalants - R03Aâ (6 ×§×', 48 ××¤××)
Agents against amoebiasis and other protozoal diseases - P01Aâ (5 ×§×', 2 ××¤××)
Agents against leishmaniasis and trypanosomiasis - P01Câ (5 ×§×', 7 ××¤××)
Agents for treatment of hemorrhoids and anal fissures for topical use - C05Aâ (5 ×§×', 11 ××¤××)
Alkylating agents - L01Aâ (6 ×§×', 48 ××¤××)
All other non-therapeutic products - V07Aâ (12 ×§×')
All other therapeutic products - V03Aâ (11 ×§×', 83 ××¤××)
Allergens - V01Aâ (×§×' ×××ª, 9 ××¤××)
Aminoglycoside antibacterials - J01Gâ (2 ×§×', 11 ××¤××)
Amphenicols - J01Bâ (×§×' ×××ª, ××£ ×××)
Anabolic steroids - A14Aâ (2 ×§×')
Androgens - G03Bâ (2 ×§×', 8 ××¤××)
Androgens and female sex hormones in combination - G03Eâ (3 ×§×', ××£ ×××)
Anesthetics, general - N01Aâ (6 ×§×', 78 ××¤××)
Anesthetics, local - N01Bâ (4 ×§×', 67 ××¤××)
Angiotensin II antagonists, combinations - C09Dâ (3 ×§×', 18 ××¤××)
Angiotensin II antagonists, plain - C09Câ (×§×' ×××ª, 51 ××¤××)
Antacids - A02Aâ (8 ×§×', 21 ××¤××)
Anterior pituitary lobe hormones and analogues - H01Aâ (4 ×§×', 21 ××¤××)
Anti-acne preparations for systemic use - D10Bâ (2 ×§×', 13 ××¤××)
Anti-acne preparations for topical use - D10Aâ (6 ×§×', 35 ××¤××)
Anti-dementia drugs - N06Dâ (2 ×§×', 51 ××¤××)
Anti-infectives - S01Aâ (5 ×§×', 38 ××¤××)
Anti-infectives - S02Aâ (×§×' ×××ª, 4 ××¤××)
Anti-infectives - S03Aâ (×§×' ×××ª, 7 ××¤××)
Anti-inflammatory agents - S01Bâ (3 ×§×', 20 ××¤××)
Anti-inflammatory agents - V10Aâ (2 ×§×', ××£ ×××)
Anti-inflammatory agents and anti-infectives in combination - S01Câ (3 ×§×', 9 ××¤××)
Anti-inflammatory and antirheumatic products, non-steroids - M01Aâ (7 ×§×', 102 ××¤××)
Anti-inflammatory/antirheumatic agents in combination - M01Bâ (2 ×§×')
Anti-parathyroid agents - H05Bâ (2 ×§×', 22 ××¤××)
Antiadrenal preparations - H02Câ (×§×' ×××ª, 4 ××¤××)
Antiadrenergic agents, centrally acting - C02Aâ (3 ×§×', ××£ ×××)
Antiadrenergic agents, ganglion-blocking - C02Bâ (3 ×§×')
Antiadrenergic agents, peripherally acting - C02Câ (2 ×§×', 11 ××¤××)
Antiandrogens - G03Hâ (2 ×§×', 5 ××¤××)
Antiarrhythmics, class I and III - C01Bâ (5 ×§×', 25 ××¤××)
Antibiotics and chemotherapeutics, combinations - D06Câ (×¨××§×)
Antibiotics for topical use - D06Aâ (2 ×§×', 14 ××¤××)
Anticestodals - P02Dâ (2 ×§×')
Anticholinergic agents - N04Aâ (3 ×§×', 6 ××¤××)
Antidepressants - N06Aâ (5 ×§×', 111 ××¤××)
Antidiarrheal micro-organisms - A07Fâ (×§×' ×××ª)
Antiemetics and antinauseants - A04Aâ (2 ×§×', 28 ××¤××)
Antiepileptics - N03Aâ (8 ×§×', 130 ××¤××)
Antifibrinolytics - B02Aâ (2 ×§×', 7 ××¤××)
Antifungals for systemic use - D01Bâ (×§×' ×××ª, 5 ××¤××)
Antifungals for topical use - D01Aâ (3 ×§×', 75 ××¤××)
Antiglaucoma preparations and miotics - S01Eâ (6 ×§×', 52 ××¤××)
Antigout preparations - M04Aâ (4 ×§×', 4 ××¤××)
Antihistamines for systemic use - R06Aâ (7 ×§×', 66 ××¤××)
Antihypertensives and diuretics in combination - C02Lâ (10 ×§×')
Antiinfectives and antiseptics, excluding combinations with corticosteroids - G01Aâ (8 ×§×', 22 ××¤××)
Antiinfectives/antiseptics in combination with corticosteroids - G01Bâ (5 ×§×')
Antimalarials - P01Bâ (7 ×§×', 5 ××¤××)
Antimetabolites - L01Bâ (3 ×§×', 84 ××¤××)
Antimigraine preparations - N02Câ (5 ×§×', 39 ××¤××)
Antimycotics for systemic use - J02Aâ (4 ×§×', 69 ××¤××)
Antinematodal agents - P02Câ (6 ×§×', 6 ××¤××)
Antiobesity preparations, excluding diet products - A08Aâ (3 ×§×', 6 ××¤××)
Antipropulsives - A07Dâ (×§×' ×××ª, 12 ××¤××)
Antipruritics, including antihistamines, anesthetics, etc. - D04Aâ (3 ×§×', 25 ××¤××)
Antipsoriatics for systemic use - D05Bâ (3 ×§×', 2 ××¤××)
Antipsoriatics for topical use - D05Aâ (4 ×§×', 17 ××¤××)

A (×××©×)

Antipsychotics - N05Aâ (11 ×§×', 179 ××¤××)
Antiseptics and disinfectants - D08Aâ (12 ×§×', 51 ××¤××)
Antispasmodics and anticholinergics in combination with other drugs - A03Eâ (2 ×§×')
Antispasmodics in combination with analgesics - A03Dâ (3 ×§×', ××£ ×××)
Antispasmodics in combination with psycholeptics - A03Câ (3 ×§×')
Antithrombotic agents - B01Aâ (7 ×§×', 194 ××¤××)
Antithyroid preparations - H03Bâ (4 ×§×', 2 ××¤××)
Antitrematodals - P02Bâ (3 ×§×')
Antivaricose therapy - C05Bâ (3 ×§×', 3 ××¤××)
Antivertigo preparations - N07Câ (×§×' ×××ª, 4 ××¤××)
Anxiolytics - N05Bâ (6 ×§×', 29 ××¤××)
Arteriolar smooth muscle, agents acting on - C02Dâ (5 ×§×', 2 ××¤××)
Ascorbic acid (vitamin C), including combinations - A11Gâ (2 ×§×')

B

Bacterial and viral vaccines - J07Câ (×§×' ×××ª, 12 ××¤××)
Bacterial vaccines - J07Aâ (14 ×§×', 27 ××¤××)
Belladonna and derivatives, plain - A03Bâ (2 ×§×', 11 ××¤××)
Beta blocking agents - C07Aâ (3 ×§×', 41 ××¤××)
Beta blocking agents and other antihypertensives - C07Fâ (2 ×§×')
Beta blocking agents and other diuretics - C07Câ (3 ×§×')
Beta blocking agents and thiazides - C07Bâ (3 ×§×')
Beta blocking agents and vasodilators - C07Eâ (2 ×§×')
Beta blocking agents, thiazides and other diuretics - C07Dâ (2 ×§×')
Beta-lactam antibacterials, penicillins - J01Câ (5 ×§×', 67 ××¤××)
Bile therapy - A05Aâ (4 ×§×', 16 ××¤××)
Blood and related products - B05Aâ (2 ×§×', 18 ××¤××)
Blood glucose lowering drugs, excluding insulins - A10Bâ (10 ×§×', 187 ××¤××)

C

Calcium - A12Aâ (2 ×§×', 15 ××¤××)
Calcium channel blockers and diuretics - C08Gâ (×§×' ×××ª)
Capillary stabilising agents - C05Câ (2 ×§×', 3 ××¤××)
Cardiac glycosides - C01Aâ (4 ×§×', 4 ××¤××)
Cardiac stimulants excluding cardiac glycosides - C01Câ (3 ×§×', 35 ××¤××)
Cardiovascular system - V09Gâ (3 ×§×', 4 ××¤××)
Central nervous system - V09Aâ (3 ×§×', 4 ××¤××)
Chemotherapeutics for topical use - D06Bâ (3 ×§×', 25 ××¤××)
Cicatrizants - D03Aâ (2 ×§×', 3 ××¤××)
Combinations of antibacterials - J01Râ (×§×' ×××ª)
Combinations of antihypertensives in ATC-group C02 - C02Nâ (×¨××§×)
Contraceptives for topical use - G02Bâ (2 ×§×', 2 ××¤××)
Corticosteroids - S02Bâ (×§×' ×××ª)
Corticosteroids - S03Bâ (×§×' ×××ª, ××£ ×××)
Corticosteroids and anti-infectives in combination - S02Câ (×§×' ×××ª, 3 ××¤××)
Corticosteroids and anti-infectives in combination - S03Câ (×§×' ×××ª)
Corticosteroids for systemic use, combinations - H02Bâ (×§×' ×××ª)
Corticosteroids for systemic use, plain - H02Aâ (2 ×§×', 40 ××¤××)
Corticosteroids, combinations with antibiotics - D07Câ (4 ×§×', 11 ××¤××)
Corticosteroids, combinations with antiseptics - D07Bâ (4 ×§×', ××£ ×××)
Corticosteroids, other combinations - D07Xâ (4 ×§×', 10 ××¤××)
Corticosteroids, plain - D07Aâ (4 ×§×', 32 ××¤××)
Cough suppressants and expectorants, combinations - R05Fâ (2 ×§×', 2 ××¤××)
Cough suppressants, excluding combinations with expectorants - R05Dâ (2 ×§×', 26 ××¤××)
Cytotoxic antibiotics and related substances - L01Dâ (3 ×§×', 22 ××¤××)

D

Decongestants and antiallergics - S01Gâ (2 ×§×', 25 ××¤××)
Decongestants and other nasal preparations for topical use - R01Aâ (5 ×§×', 52 ××¤××)
Diagnostic agents - S01Jâ (2 ×§×', 3 ××¤××)
Diet formulations for treatment of obesity - V06Aâ (×§×' ×××ª)
Digestives, including enzymes - A09Aâ (3 ×§×', 7 ××¤××)
Direct acting antiviral drugs - J05Aâ (12 ×§×', 152 ××¤××)
Diuretics and potassium-sparing agents in combination - C03Eâ (2 ×§×', ××£ ×××)
Dopaminergic agents - N04Bâ (5 ×§×', 59 ××¤××)
Drugs affecting bone structure and mineralization - M05Bâ (4 ×§×', 45 ××¤××)
Drugs for bile therapy and lipotropics in combination - A05Câ (×¨××§×)
Drugs for constipation - A06Aâ (7 ×§×', 42 ××¤××)
Drugs for functional gastrointestinal disorders - A03Aâ (6 ×§×', 13 ××¤××)
Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) - A02Bâ (5 ×§×', 67 ××¤××)
Drugs for treatment of lepra - J04Bâ (×§×' ×××ª)
Drugs for treatment of tuberculosis - J04Aâ (6 ×§×', 2 ××¤××)
Drugs used in addictive disorders - N07Bâ (3 ×§×', 33 ××¤××)

D (×××©×)

Drugs used in benign prostatic hypertrophy - G04Câ (3 ×§×', 39 ××¤××)

E

Ectoparasiticides, including scabicides - P03Aâ (4 ×§×', 4 ××¤××)
Electrolytes with carbohydrates - A07Câ (×§×' ×××ª)
Emollients and protectives - D02Aâ (7 ×§×', 4 ××¤××)
Enzymes - D03Bâ (×§×' ×××ª)
Estrogens - G03Câ (4 ×§×', 38 ××¤××)
Expectorants, excluding combinations with cough suppressants - R05Câ (2 ×§×', 25 ××¤××)

G

Glycogenolytic hormones - H04Aâ (×§×' ×××ª, 2 ××¤××)
Gonadotropins and other ovulation stimulants - G03Gâ (2 ×§×', 23 ××¤××)

H

Hemodialytics and hemofiltrates - B05Zâ (2 ×§×')
Hepatic and reticulo endothelial system - V09Dâ (3 ×§×')
High-ceiling diuretics - C03Câ (5 ×§×', 10 ××¤××)
Hormonal contraceptives for systemic use - G03Aâ (4 ×§×', 40 ××¤××)
Hormone antagonists and related agents - L02Bâ (4 ×§×', 69 ××¤××)
Hormones and related agents - L02Aâ (4 ×§×', 19 ××¤××)
Hypnotics and sedatives - N05Câ (10 ×§×', 44 ××¤××)
Hypothalamic hormones - H01Câ (3 ×§×', 40 ××¤××)

I

I.v. solution additives - B05Xâ (4 ×§×', 58 ××¤××)
I.v. solutions - B05Bâ (3 ×§×', 75 ××¤××)
Immune sera - J06Aâ (×§×' ×××ª, 2 ××¤××)
Immunoglobulins - J06Bâ (4 ×§×', 44 ××¤××)
Immunostimulants - L03Aâ (4 ×§×', 50 ××¤××)
Immunosuppressants - L04Aâ (12 ×§×', 279 ××¤××)
Infant formulas - V06Câ (×§×' ×××ª)
Inflammation and infection detection - V09Hâ (3 ×§×', ××£ ×××)
Insecticides and repellents - P03Bâ (2 ×§×')
Insulins and analogues - A10Aâ (5 ×§×', 33 ××¤××)
Intestinal adsorbents - A07Bâ (3 ×§×', 7 ××¤××)
Intestinal anti-infectives - A07Aâ (4 ×§×', 14 ××¤××)
Intestinal anti-inflammatory agents - A07Eâ (3 ×§×', 36 ××¤××)
Iodine therapy - H03Câ (×§×' ×××ª)
Iron preparations - B03Aâ (5 ×§×', 21 ××¤××)
Irrigating solutions - B05Câ (3 ×§×', 46 ××¤××)

L

Lipid modifying agents, combinations - C10Bâ (2 ×§×', 24 ××¤××)
Lipid modifying agents, plain - C10Aâ (5 ×§×', 123 ××¤××)
Liver therapy, lipotropics - A05Bâ (×§×' ×××ª, ××£ ×××)
Local anesthetics - S01Hâ (×§×' ×××ª, 5 ××¤××)
Low-ceiling diuretics, excluding thiazides - C03Bâ (6 ×§×', 2 ××¤××)
Low-ceiling diuretics, thiazides - C03Aâ (4 ×§×', 8 ××¤××)

M

Macrolides, lincosamides and streptogramins - J01Fâ (3 ×§×', 28 ××¤××)
Magnetic resonance imaging contrast media - V08Câ (3 ×§×', 8 ××¤××)
Medicated dressings - D09Aâ (3 ×§×', 8 ××¤××)
Monoclonal antibodies and antibody drug conjugates - L01Fâ (9 ×§×', 79 ××¤××)
Multivitamins, combinations - A11Aâ (2 ×§×', 4 ××¤××)
Multivitamins, plain - A11Bâ (×§×' ×××ª, ××£ ×××)
Muscle relaxants, centrally acting agents - M03Bâ (4 ×§×', 11 ××¤××)
Muscle relaxants, directly acting agents - M03Câ (×§×' ×××ª, ××£ ×××)
Muscle relaxants, peripherally acting agents - M03Aâ (4 ×§×', 17 ××¤××)
Mydriatics and cycloplegics - S01Fâ (2 ×§×', 6 ××¤××)

N

Nasal decongestants for systemic use - R01Bâ (×§×' ×××ª, 48 ××¤××)
Non-selective calcium channel blockers - C08Eâ (2 ×§×')

O

Ocular vascular disorder agents - S01Lâ (×§×' ×××ª, 9 ××¤××)
Opioids - N02Aâ (8 ×§×', 87 ××¤××)
Other agents acting on the renin-angiotensin system - C09Xâ (×§×' ×××ª, 2 ××¤××)
Other alimentary tract and metabolism products - A16Aâ (3 ×§×', 47 ××¤××)
Other anabolic agents - A14Bâ (×¨××§×)
Other analgesics and antipyretics - N02Bâ (5 ×§×', 151 ××¤××)
Other antianemic preparations - B03Xâ (×§×' ×××ª, 59 ××¤××)
Other antibacterials - J01Xâ (6 ×§×', 28 ××¤××)
Other antidiarrheals - A07Xâ (×§×' ×××ª)
Other antihypertensives - C02Kâ (5 ×§×', 28 ××¤××)
Other antineoplastic agents - L01Xâ (14 ×§×', 143 ××¤××)
Other beta-lactam antibacterials - J01Dâ (7 ×§×', 83 ××¤××)
Other cardiac preparations - C01Eâ (3 ×§×', 15 ××¤××)
Other cold preparations - R05Xâ (×¨××§×)
Other dermatological preparations - D11Aâ (6 ×§×', 30 ××¤××)

(200 ××§×××××) (200 ×××××)

השינוי האחרון נעשה בֹ־27 בדצמבר 2013 ב־09:34